RegulatoryJul 17, 2026, 04:06 PM
Clearmind Medicine Commends Federal Momentum for Psychedelic Therapies
AI Summary
Clearmind Medicine Inc. commended significant federal and inter-agency developments supporting innovative treatments for serious neuropsychiatric and addiction disorders. The company highlighted final FDA guidance on psychedelic clinical investigations and new collaborative initiatives among key U.S. health agencies. Clearmind, a clinical-stage biotechnology company, views these developments as crucial for expanding therapeutic options for patients, particularly as its lead candidate, CMND-100, is in Phase I/IIa clinical trials for Alcohol Use Disorder.
Key Highlights
- Clearmind Medicine Inc. noted significant federal momentum in advancing psychedelic-based therapies.
- Developments include final FDA guidance on psychedelic clinical investigations.
- New inter-agency collaborations involve HHS, VA, FDA, NIDA, ARPA-H, and HRSA.
- These initiatives support innovative treatments for neuropsychiatric and addiction disorders.
- Clearmind's lead candidate, CMND-100, is in FDA-cleared Phase I/IIa trials for Alcohol Use Disorder.
- CMND-100 trials are being conducted at Yale University and Johns Hopkins.
Price Impact
More from CMND